Bidda Sovereign Intelligence · 10,090 Verified Nodes · 39 Sovereign Pillars

FDA Final Rule on Laboratory Developed Tests (LDTs) - 21 CFR 809.3 Amendment and 4-Year Phaseout (May 2024)

FDA's Final Rule on Medical Devices - Laboratory Developed Tests (89 FR 37286, published 6 May 2024, effective 5 July 2024) amends 21 CFR Section 809.3 to…

What FDA Final Rule on Laboratory Developed Tests (LDTs) - 21 CFR 809.3 Amendment and 4-Year Phaseout (May 2024) requires

FDA's Final Rule on Medical Devices - Laboratory Developed Tests (89 FR 37286, published 6 May 2024, effective 5 July 2024) amends 21 CFR Section 809.3 to make explicit that in vitro diagnostic products (IVDs) are medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act) including when manufactured by a laboratory. The rule phases out FDA's general enforcement discretion for LDTs over five stages: Stage 1 (1 year after publication, ~May 2025) - Medical Device Reporting (MDR), correction and removal reporting, and Quality System (QS) Section 820.198 complaint files; Stage 2 (2 years, ~May 2026) - registration and listing under 21 U.S.C. 360 and 21 CFR Parts 607 and 807; labeling under 21 U.S.C. 352 and 21 CFR Parts 801 and 809 Subpart B; investigational use under 21 U.S.C. 360j(g) and 21 CFR Part 812; Stage 3 (3 years, ~May 2027) - full QS regulation under 21 CFR Part 820; Stage 4 (3.5 years, ~Nov 2027) - premarket review for high-risk IVDs offered as LDTs; Stage 5 (4 years, ~May 2028) - premarket review for moderate-risk and low-risk IVDs requiring premarket submission. Continuing enforcement discretion applies to: currently marketed IVDs offered as LDTs; HCT/P-related LDTs in blood and cell-and-gene therapy laboratories; LDTs for unmet needs; LDTs for rare diseases; public-health surveillance LDTs; forensic LDTs.

Pillar: Medical & Healthcare · Authority: Federal Register - FDA Final Rule, Medical Devices: Laboratory Developed Tests (6 May 2024) · Version: 1.0.1 · Last updated:

Primary source: https://www.federalregister.gov/documents/2024/05/06/2024-08935/medical-devices-laboratory-developed-tests

SHA-256 integrity: 4c48647712e192e5d5915b0f60a0db886756625fa4aabddfdeeb252f9cd49abf

Primary Citations — 18 traced to source

  • FDA Final Rule, Medical Devices; Laboratory Developed Tests, 89 FR 37286 (6 May 2024)
  • 21 CFR Section 809.3 (as amended) - IVD definition includes laboratory manufacturers

+ 16 more citations (full bibliography, deterministic workflow, actionable schema and crosswalks) included in the vault unlock — $0.01 via Skyfire / L402 / Direct Base USDC.

Access

⚠ Important: Human Verification Required

Bidda compliance nodes are reference intelligence, not legal advice. Every node must be reviewed by a qualified compliance professional or legal counsel before implementation in any enterprise workflow, regulated system, or compliance programme. See bidda.com/disclaimer for full terms.